New developments in lung endothelial heterogeneity: Von Willebrand factor, P-selectin, and the Weibel-Palade body.

abstract：:Heparin is a familiar anticoagulant drug with properties that may impede tumor growth; it modifies properties of cells that contribute to malignant dissemination such as angiogenesis, growth factor and protease activity, immune function, proliferation, and gene expression. Heparin has antitumor effects in animal model...

journal_title：Seminars in thrombosis and hemostasis

authors： Zacharski LR,Ornstein DL,Mamourian AC

更新日期：2000-01-01 00:00:00

abstract：:Bleeding can be a serious complication of surgery, and topical thrombin is widely used as an adjunct to hemostasis in diverse surgical settings. The potent hemostatic properties of thrombin derive from its ability to activate platelets directly to aggregate and adhere to damaged vessels and to catalyze the formation s...

journal_title：Seminars in thrombosis and hemostasis

authors： Bishop PD,Lewis KB,Schultz J,Walker KM

更新日期：2006-04-01 00:00:00

abstract：:In order to obtain a global assessment of circulating clopidogrel-related products and of the excretion of the drug, the pharmacokinetic behavior and the excretion balance of 14C radioactivity following the administration of a single dose of 75 mg of 14C-labeled clopidogrel were compared in 6 clopidogrel-free healthy ...

journal_title：Seminars in thrombosis and hemostasis

authors： Lins R,Broekhuysen J,Necciari J,Deroubaix X

更新日期：1999-01-01 00:00:00

abstract：:The management of childhood acute idiopathic thrombocytopenic purpura is controversial, with recent guidelines highlighting the lack of suitable evidence upon which to base management decisions. Three European centers have used an expectant policy and results over the past decade demonstrate that this is safe and conv...

journal_title：Seminars in thrombosis and hemostasis

authors： Bolton-Maggs PH,Dickerhoff R,Vora AJ

更新日期：2001-06-01 00:00:00

abstract：:Approximately 5 to 7% of patients with hemophilia A have inhibitory antibodies to factor (F) VIII, which increases to approximately 13% in patients with severe disease. The strongest determinant of the risk of inhibitor development identified is the type of mutation in the FVIII gene that gives rise to the disease. Ho...

journal_title：Seminars in thrombosis and hemostasis

authors： Lee CA,Lillicrap D,Astermark J

更新日期：2006-06-01 00:00:00

abstract：:Antithrombin activity should probably be determined in persons with early onset of recurrent thrombosis, especially if a family history is present. The initial screening test should be a heparin cofactor assay optimized to reduce the contribution of heparin cofactor II. If the heparin cofactor assay is low, an antigen...

journal_title：Seminars in thrombosis and hemostasis

authors： Tollefsen DM

更新日期：1990-04-01 00:00:00

abstract：:These results show that heparin and dextran sulfate protect endothelial cells from oxygen-free radicals. Heparan sulfate and dermatan sulfate showed mild protection when measuring cell viability but none when examining the presence of LDH in media. These GAGs are obviously not as effective as heparin and dextran sulfa...

journal_title：Seminars in thrombosis and hemostasis

authors： Hiebert L,Liu JM

更新日期：1991-01-01 00:00:00

abstract：:Hemorrhagic complications during therapy with anticoagulant drugs have long been considered as simply and directly related to overdosage. Yet, such adverse events have also been observed in patients correctly anticoagulated, i.e., within the therapeutic range, thus demonstrating that the predictive value of laboratory...

journal_title：Seminars in thrombosis and hemostasis

authors： Toulemonde F

更新日期：1996-01-01 00:00:00

abstract：:In order to assess inhibitor development in previously untreated patients (PUPs) with severe (factor VIII [FVIII]<1%) and moderate (FVIII 1 to 5%) hemophilia A, a prospective study was initiated in 1976. During the 23-year study period, 72 hemophiliacs were frequently exposed prophylactically or on demand to plasma-de...

journal_title：Seminars in thrombosis and hemostasis

authors： Kreuz W,Ettingshausen CE,Zyschka A,Oldenburg J,Saguer IM,Ehrenforth S,Klingebiel T

更新日期：2002-06-01 00:00:00

abstract：:Measurement of D-dimer (fibrin degradation product) is important for determining not only the activation of fibrinolysis but also the severity of a hypercoagulable state. However, fibrin degradation products are in variable, and the reactivity to cross-linked fibrin degradation products produced during fibrin degradat...

journal_title：Seminars in thrombosis and hemostasis

authors： Matsuo T,Kobayashi H,Kario K,Suzuki S

更新日期：2000-01-01 00:00:00

abstract：:The proinflammatory cytokine storm associated with coronavirus disease 2019 (COVID-19) negatively affects the hematological system, leading to coagulation activation and endothelial dysfunction and thereby increasing the risk of venous and arterial thrombosis. Coagulopathy has been reported as associated with mortalit...

journal_title：Seminars in thrombosis and hemostasis

authors： Zadow EK,Wundersitz DWT,Hughes DL,Adams MJ,Kingsley MIC,Blacklock HA,Wu SSX,Benson AC,Dutheil F,Gordon BA

更新日期：2020-10-01 00:00:00

abstract：:Homocysteine has been identified as an independent risk factor for atherosclerotic and thrombotic disease. Both arterial (cerebrovascular, carotid, coronary, and peripheral arterial) and veno-occlusive disease, jointly termed vascular occlusive disease (VOD) in this review, have been associated with hyperhomocysteinem...

journal_title：Seminars in thrombosis and hemostasis

authors： Guba SC,Fonseca V,Fink LM

更新日期：1999-01-01 00:00:00

abstract：:Site-directed thrombin inhibitors are being currently assessed clinically for their antithrombotic efficacy. Although these agents are claimed to be specific and direct thrombin inhibitors, their mechanism of inhibition varies. The objective of these studies was to compare four such agents in in vitro systems and to a...

journal_title：Seminars in thrombosis and hemostasis

authors： Callas DD,Hoppensteadt D,Fareed J

更新日期：1995-01-01 00:00:00

abstract：:In the course of fibrin formation, the D-domains of adjacent fibrin molecules within the fibrin polymer are covalently linked by factor XIIIa, leading to the formation of a D-domain dimer. Proteolysis of this cross-linked fibrin generates fibrin fragments D-dimer and E as terminal products. Fragment D-dimer therefore ...

journal_title：Seminars in thrombosis and hemostasis

authors： Dempfle CE

更新日期：2000-01-01 00:00:00

abstract：:Despite numerous past and ongoing efforts, there remains significant variation in results from assays for the major antiphospholipid antibodies (aPL), namely anticardiolipin (aCL), anti-beta2 glycoprotein I (anti-beta2GPI), and lupus anticoagulant (LA). There is therefore a need to produce comprehensive guidelines on ...

journal_title：Seminars in thrombosis and hemostasis

authors： Wong RC,Favaloro EJ

更新日期：2008-06-01 00:00:00

abstract：:Protein S is a vitamin K-dependent plasma glycoprotein circulating in plasma at a concentration of around 350 nM. Approximately 60% of protein S in human plasma is bound to the complement regulatory protein C4b-binding protein (C4BP) in a high-affinity, high-molecular-weight complex. Protein S in plasma has multiple a...

journal_title：Seminars in thrombosis and hemostasis

authors： Dahlbäck B

更新日期：2018-03-01 00:00:00

abstract：:Thrombophilia can be defined as an increased tendency to thrombosis. There are several defined risk factors for thrombosis, and these are generally separated into acquired and congenital factors. Congenital risk factors include deficiencies or defects in natural anticoagulants, such as antithrombin, protein C and prot...

journal_title：Seminars in thrombosis and hemostasis

authors： Favaloro EJ

更新日期：2005-02-01 00:00:00

abstract：:Protein C inhibitor (PCI) is a serine protease inhibitor and was originally identified as an inhibitor of activated protein C (APC). However, PCI is not specific for APC and also inhibits several proteases involved in coagulation, fibrinolysis, cancer, wound healing, and fertility. The biological function of PCI is un...

journal_title：Seminars in thrombosis and hemostasis

authors： Meijers JC,Herwald H

更新日期：2011-06-01 00:00:00

abstract：:D-dimer is the biochemical gold standard for diagnosing a variety of thrombotic disorders, but result reporting is heterogeneous in clinical laboratories. A specific five-item questionnaire was developed to gain a clear picture of the current standardization of D-dimer test results. The questionnaire was opened online...

journal_title：Seminars in thrombosis and hemostasis

authors： Lippi G,Tripodi A,Simundic AM,Favaloro EJ

更新日期：2015-04-01 00:00:00

abstract：:Currently, in Germany, there is a successful program where patients monitor their own coagulation status through self-testing. The advent of a new generation of coagulometers has allowed more and more patients to use self-testing to monitor their coagulation status. The development of a structured training program by ...

journal_title：Seminars in thrombosis and hemostasis

authors： Taborski U,Müller-Berghaus G

更新日期：1999-01-01 00:00:00

abstract：:Coagulation factor XII (FXII), formerly known as Hageman factor, is a plasma glycoprotein which exerts a kaleidoscope of biological functions, including the initiation of the intrinsic pathway of blood coagulation, the activation of the kallikrein-kinin system, and the generation of bradykinin and angiotensin. The lar...

journal_title：Seminars in thrombosis and hemostasis

authors： Danese E,Montagnana M,Lippi G

更新日期：2016-09-01 00:00:00

abstract：:Trauma remains one of the major causes of death and disability all over the world. Uncontrolled blood loss and trauma-induced coagulopathy represent preventable causes of trauma-related morbidity and mortality. Treatment may consist of allogeneic blood product transfusion at a fixed ratio or in an individualized goal-...

journal_title：Seminars in thrombosis and hemostasis

authors： Stein P,Kaserer A,Spahn GH,Spahn DR

更新日期：2017-06-01 00:00:00

abstract：:Of all the coagulation factor deficiencies, only deficiency of factor XIII (FXIII) and fibrinogen are associated with pregnancy loss. FXIII deficiency and a complete or partial deficiency of fibrinogen are associated with bleeding since childhood, impaired wound repair, and recurrent spontaneous abortions. Both FXIII ...

journal_title：Seminars in thrombosis and hemostasis

authors： Inbal A,Muszbek L

更新日期：2003-04-01 00:00:00

abstract：:Vatreptacog alfa is a genetically engineered variant of recombinant factor VIIa (rFVIIa) containing three amino acid changes. Aspartic acid, valine, and glutamine residues replace valine, glutamic acid, and methionine at positions 158, 296, and 298, respectively. These substitutions result in considerable enhancement ...

journal_title：Seminars in thrombosis and hemostasis

authors： Persson E,Olsen OH,Bjørn SE,Ezban M

更新日期：2012-04-01 00:00:00

abstract：:Neonatal hemostasis differs qualitatively, but in particular quantitatively, from hemostasis in older children and adults. Nevertheless, hemostasis in healthy neonates is functionally stable with no tendency to bleeding or thrombotic complications. In sick neonates, however, risk factors may disrupt this equilibrium a...

journal_title：Seminars in thrombosis and hemostasis

authors： van Ommen CH,Sol JJ

更新日期：2016-10-01 00:00:00

abstract：BACKGROUND:The normalized dilute Russell viper venom time (DRVVT) ratio provides a robust assay methodology for lupus anticoagulant (LA) detection. OBJECTIVES:We evaluated six normalized DRVVT LA screen and confirm systems for inter-method consistency. Reagents were purchased from Diagnostica Stago, Inc. (Parsippany, ...

journal_title：Seminars in thrombosis and hemostasis

authors： McGlasson DL,Fritsma GA

更新日期：2013-04-01 00:00:00

abstract：:Mixing patient and normal plasma has been used for many years to assist with making decisions on which direction to proceed for further investigation of abnormally prolonged coagulation tests, namely, either individual coagulation factor measurement or the search for circulating anticoagulants. Mixing tests, however, ...

journal_title：Seminars in thrombosis and hemostasis

authors： Tripodi A

更新日期：2012-06-01 00:00:00

abstract：:Congenital amegakaryocytic thrombocytopenia (CAMT, MIM #604498) is a rare inherited bone marrow failure syndrome presenting as isolated hypomegakaryocytic thrombocytopenia at birth without other characteristic physical anomalies. Most of the patients develop a severe aplastic anemia and trilineage cytopenia during the...

journal_title：Seminars in thrombosis and hemostasis

authors： Ballmaier M,Germeshausen M

更新日期：2011-09-01 00:00:00

abstract：:A simple nonisotopic method for the quantitation of FPA in biologic samples has been developed utilizing a competitive enzyme immunoassay technique. The performance characteristics of these assays have been investigated in both the experimental and clinical settings and were found to be satisfactory for the routine cl...

journal_title：Seminars in thrombosis and hemostasis

authors： Amiral J,Walenga JM,Fareed J

更新日期：1984-10-01 00:00:00

abstract：:The contribution of platelet dysfunction to the impaired hemostasis after cardiac surgery remains to be established, because there is no sensitive method to assess platelet function. Measurement of the shear-induced pathway of platelet function, an important mechanism in inducing hemostasis, became possible by a novel...

journal_title：Seminars in thrombosis and hemostasis

authors： Tabuchi N,Tigchelaar I,van Oeveren W

更新日期：1995-01-01 00:00:00